Data from FDA (Food and Drug Administration, USA) - Curated by EPG Health - Last updated 01 June 2018

Indication(s)

INDICATIONS AND USAGE GLOFIL-125 (Sodium Iothalamate I-125 Injection) is indicated for evaluation of glomerular filtration in the diagnosis or monitoring of patients with renal disease.

Learning Zones

An epgonline.org Learning Zone (LZ) is an area of the site dedicated to providing detailed self-directed medical education about a disease, condition or procedure.

Transplantation

Transplantation

See information on best practice in solid organ transplantation, and expert discussions on related hot topics.

Fluid Management

Fluid Management

Are you up-to-date with the latest evidence of effective procedures for fluid management?

+ 2 more

Chronic Obstructive Pulmonary Disease (COPD)

Chronic Obstructive Pulmonary Disease (COPD)

View highlights from recent congresses presented in new expert videos with leading physicians.

+ 7 more

Load more

Related Content

Advisory information

contraindications
CONTRAINDICATIONS GLOFIL-125 should not be administered via a central venous line.
Special warnings and precautions
PRECAUTIONS General As in the use of any radioactive material, care should be taken to minimize radiation exposure to the patient, consistent with proper patient management, and to insure minimum radiation exposure to occupational workers. Radiopharmaceuticals should be used only by physicians who are qualified by training and experience in the safe use and handling of radionuclides. Rapid or bolus-like injections should be avoided. Carcinogenesis, Mutagenesis, Impairment of Fertility No long-term animal studies have been performed to evaluate carcinogenic potential, mutagenic potential, or whether this drug affects fertility in males or females. Pregnancy Category C Animal reproduction studies have not been conducted with GLOFIL-125. It is also not known whether GLOFIL-125 can cause fetal harm when administered to a pregnant woman or can affect reproduction capacity. GLOFIL-125 should be given to a pregnant woman only if clearly needed. Nursing Mothers Radioiodine is excreted in human milk during lactation. It is not known whether GLOFIL-125 is excreted in human milk. Therefore, formula feedings should be substituted for breast feedings. Pediatric Use Safety and effectiveness in children have not been established.
Adverse reactions
ADVERSE REACTIONS None Reported

Usage information

Dosing and administration
Dosage The suggested dose range employed in the average patient (70 kg) is as follows: Continuous intravenous infusion: 20 to 100 μCi (0.74-3.7 megabecquerels) (Sigman, et al (1) method). Single intravenous injection: 10 to 30 µCi (0.37-1.11 megabecquerels) (Cohen, et al (2) method). The patient dose should be measured by a suitable radioactivity calibration system immediately prior to administration. Technique Continuous intravenous infusion Sigman1 method I. Preparation: 1. Adequate diuresis (a urine flow exceeding 3 mL/min.) is established, preferably by an oral water load of 1,500 mL two hours prior to the beginning of the clearance study. 2. It is not necessary to withhold breakfast or admit the patient the night before. II. Procedure: 1. After the establishment of adequate diuresis, a number 14 or 16 French Foley catheter is aseptically inserted into the bladder. 2. An intravenous infusion of Lactated Ringers (Hartmanns) solution is started in each arm, one to maintain a site for injection of the GLOFIL-125, the other to serve as a site for serial withdrawal of blood. A two-way stopcock connects the needle and intravenous tubing of each arm. 3. The dose is equally divided into (1) an intravenous priming dose to be injected as is and (2) a sustaining dose to be diluted in 30 to 60 mL of isotonic sodium chloride, depending on how many collection periods are anticipated. 4. The priming dose is slowly injected into one arm. This is immediately followed by infusion of the sustaining solution through the same site, usually at the rate of 0.5 mL/min., by means of an automatic pump. During this infusion, the Lactated Ringers solution in the same arm is discontinued, and 40 to 45 minutes are allowed for equilibration in order to reach a state of constant plasma concentration of radioactivity. 5. After attaining equilibrium, consecutive 15 minute collection periods are started. From the arm opposite the injection site, 5 mL of blood (allowing duplicate plasma counting volumes) is drawn six minutes prior to the midpoint of each collection period, placed in heparinized tubes, mixed, and centrifuged. The blood samples may be obtained through the two-way stopcock after discarding the first 30 mL aspirated into the syringe. This 30 mL contains the contents of the tubing, including infusion fluid, and must be cleared in order to obtain an undiluted blood sample. If desired, this step may be eliminated and blood samples obtained by direct venipuncture. 6. During each collection period, total urine must be accurately collected and the volume accurately measured. Three such consecutive collection periods are sufficient for most clinical studies. III. Clearance Calculations: 1. Aliquots (1 mL each) of plasma and urine from each collection period are counted in a standard gamma-ray scintillation well detector. 2. All counts are corrected for background activity. 3. Glomerular filtration rate is calculated by the formula C=UV/P, in which: C = glomerular filtration rate in mL/min U= urinary concentration of radioactivity in net counts/min/mL V= urinary flow rate in mL/min P = plasma concentration of radioactivity in net counts/min/mL 4. Average glomerular filtration rate (GFR) is calculated from the rates for the individual collection periods. GFR can be expressed in terms of body weight (mL/min/kg) or body surface area (mL/min/m2). 5. Unilateral glomerular filtration rates can be determined by the same technique by utilizing ureteral catheterization. Single intravenous injection Cohen2 method: The method of Cohen, et al2 requires little preparation, few and small blood samples, no bladder catheterization, and no constant intravenous infusion. It is simple to perform, rapid, and utilizes equipment which is readily available in most modern laboratories. I. Preparation: 1. Lugol's solution, 3 drops orally, three times a day, is administered for one or two days prior to the test. No diet or water restriction is necessary. 2. Oral water load is begun one hour before starting the test. Start with 20 mL/kg and force any clear liquids (unless contraindicated) until the test is complete. II. Procedure: Record actual times for the collection of the blood and urine samples. 1. Empty the bladder and label the urine Urine control. 2. Inject 10-30 µCi GLOFIL-125 intravenously; wait 30 to 60 minutes. 3. Collect the entire urine and label Urine discard. 4. Draw 4 to 5 mL of blood into a heparinized syringe. Label Plasma #1. 5. After another 30 to 60 minutes, collect the entire urine and label Urine #1. 6. Immediately draw another blood specimen. Label Plasma #2. 7. After final 30 to 60 minute wait, collect the urine. Label Urine #2. 8. Draw the last blood specimen immediately. Label Plasma #3. III. Clearance Calculations: 1. Radioactivity of one mL aliquots of both urine and plasma are determined using a well-scintillation detector with a single channel pulse-height analyzer. Sufficiently reproducible counts are usually obtained with time settings of 2 minutes for urine samples and 20 minutes for the plasma samples. Calculations of the clearance rates are made by using the formula:(1) C = C = UV/P + 1.73/SA where C = glomerular filtration rate in mL/min/1.73 m2 U = urine radioactivity in counts/min/mL V = urine flow rate in mL/min P= mean plasma radioactivity in counts/min/mL SA= body surface area in m2 Radiation Dosimetry The estimated absorbed radiation doses to an average (70 kg) patient from an intravenous dose of 100 µCi (3.7 megabecquerels) of GLOFIL-125 are shown in Table 4. Calculations assume that there is 1% free iodide in the preparation and that the thyroid uptake of the iodine is 25%. image description

More information

Category Value
Authorisation number NDA017279
Agency product number 31J5U3Q9ZN
Orphan designation No
Product NDC 50914-7729
Date Last Revised 23-05-2018
Type HUMAN PRESCRIPTION DRUG
Storage and handling Storage Refrigerate the product upon receipt at 2°C to 8°C.
Marketing authorisation holder Iso-Tex Diagnostics, Inc.